With diabetes medicine heart failure risk in 2 times

With diabetes medicine heart failure risk in 2 times


　Diabetes remedy Avandia ([abandeia] and general name: rosiglitazone [roshiguritazon], in the Japanese country not yet approval) or [akutosu] ([pioguritazon]) as for the patient who uses each of them, the report that, was published to the medical magazine “Diabetes Care” August edition the emergence risk of heart failure is 2 times in comparison with the patient who is not used. The same family ([chiazorijin] system) with the medicine which belongs, the diabetes patient who exceeds 3,000,000 person in the United States has used Avandia and [akutosu]. In current label indication, in order to avoid the combined use with the use and the insulin with the grave heart failure patient, it is warned, but according to the latest knowledge, you say that risk increase could recognize to also the patient who does not correspond to this.

　The american food medical supply bureau which is announced to the preceding day of this report (FDA) in the research by the review team, when Avandia the risk which brings heart obstacle in comparison with [akutosu], is high substantially, the result was shown. According to the New York times paper, with the patient who has already used the insulin as for the side effect it is assumed to combined use with [akutosu] and the insulin vis-a-vis the risk due to especially Avandia being large, that it is not. This data is something which relates to the sale continuation of Avandia, whether or not the profit due to remedy exceeds risk when is important, one person of the team of FDA has expressed.

　In research “of Diabetes Care” publication, the American [ueikuhuoresuto] Wake Forest university (North Carolina) Sonal Singh doctors of the medical department, collecting the data patient 70,000 8,000 or more either Avandia or [akutosu] is used. As a result, besides the fact that it could recognize redoubling the heart failure risk, what you can see risk increase as high dosage low with whichever of dosage was ascertained. Average period to heart failure emergence from start of use of medicine 24 weeks. 25% of emergence examples under 60 not to be restricted years old and, to just the senior citizen, both the man and woman being seen it was recognized. As for the research group, as for cause of risk increase that we have presumed, whether it is not something due to moisture storage you have expressed that it is necessary to amend the current guideline.

　This year (2007) when the American Cleveland clinic (Ohio state) Steven E. Nissen, heart seizure risk 43% increases with the use of Avandia, we announce knowledge to May, argument is continued even now. According to the New York times, as for public information charge Mary Anne Rhyne of the production original [gurakuso] [sumisukurain] corporation of Avandia, as for opinion of the same company which we assume that the same medicine is safe, vis-a-vis the review of FDA, you have expressed that it does not change. With the data of the same company increase of the heart blood vessel death with Avandia is not recognized, you say that either difference of heart seizure emergence ratio is not recognized with the other medicine. Andy Zambanini doctor of the same company clinical development patsy says that presently FDA and negotiation are continued concerning the new alarm display regarding heart failure.

　But as for Nissen, as for the patient who examines the use of Avandia the doctor it should consult well, just this news should stop the medicine which presently has been used for the reason, unless, opinion. The american diabetes association (ADA) Larry Deeb, if you use each medicine just, insists that it is safe. But as for the heart failure risk by both medicines in 50 1 people, if it is possible to ascertain the 1 people, to express that it is possible to remedy 49 people who remain safely because you can see the risk increase of heart failure and the heart seizure, saying, if it is not and uses the necessity to discontinue marketing both medicines appropriately it has expressed opinion that it is the useful medicine.

(Compilation gathering =FDA as for Advisory Committee July 31st at the commission which is held, as for possibility of the heart diseased risk increase of Avandia although it recognized, sale continuation of the same medicine was approved with majority of 22 to 1.)